

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)



(10) International Publication Number
WO 2024/239000 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/166 (2006.01)
A61K 31/47 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/030109

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,157 18 May 2023 (18.05.2023) US
63/564,028 12 March 2024 (12.03.2024) US

(71) Applicant: **ENVEDA THERAPEUTICS, INC.** [US/US];
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).

(72) Inventors: **RAMDAS, Vidya**; c/o Enveda Therapeutics,
India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pan-
durangapuram, Visakhapatnam AP 530003 (IN). **JAD-
HAV, Prabhakar Kondaji**; c/o Enveda Therapeutics,
Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301
(US). **WALKE, Deepak Sahebrao**; c/o Enveda Thera-
peutics, India, Pvt. Ltd., F. No. 502, Prayaga Residen-
cy, Pandurangapuram, Visakhapatnam AP 530003 (IN).
KARATHANASIS, Sotirios K; c/o Enveda Therapeutics,
Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301

(US). **NORMAN, Bryan Hurst**; c/o Enveda Therapeu-
tics, Inc., 5700 Flatiron Parkway, Boulder, Colorado
80301 (US). **YU, Marvin**; c/o Enveda Therapeutics, Inc.,
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).
HIGHTOWER, Kendra E.; c/o Enveda Therapeutics,
Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301
(US). **MEMON, Tosifa**; c/o Enveda Therapeutics, Inc.,
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).

(74) Agent: **CHOI, Anita** et al.; Morrison & Foerster LLP, 425
Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: G-PROTEIN COUPLED RECEPTOR ANTAGONIST





FIG. 1



(I)

(57) Abstract: The present disclosure relates generally to compounds, compositions, and methods for treating a variety of diseases and conditions using a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, or derivative thereof.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

27 March 2025 (27.03.2025)